Primary hyperaldosteronism historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
* Primary hyperaldosteronism (Conn's syndrome) was described for the first time by the Polish internist Michał Lityński.<ref name="pmid17642209">{{cite journal |vauthors=Kucharz EJ |title=[Michał Lityński--a forgotten author of the first description on primary hyperaldosteronism] |language=Polish |journal=Pol. Arch. Med. Wewn. |volume=117 |issue=1-2 |pages=57–8 |year=2007 |pmid=17642209 |doi= |url= |issn=}}</ref> | * Primary hyperaldosteronism (Conn's syndrome) was described for the first time by the Polish internist Michał Lityński.<ref name="pmid17642209">{{cite journal |vauthors=Kucharz EJ |title=[Michał Lityński--a forgotten author of the first description on primary hyperaldosteronism] |language=Polish |journal=Pol. Arch. Med. Wewn. |volume=117 |issue=1-2 |pages=57–8 |year=2007 |pmid=17642209 |doi= |url= |issn=}}</ref> | ||
* In 1955, Dr Jerome W. Conn the American endocrinologist first described the condition and named it Conn's syndrome. <ref>Conn JW, Louis LH. ''Primary aldosteronism: a new clinical entity.'' Trans Assoc Am Physicians 1955;68:215-31; discussion, 231-3. PMID 13299331.</ref> | * In 1955, Dr Jerome W. Conn the American endocrinologist first described the condition and named it Conn's syndrome. <ref>Conn JW, Louis LH. ''Primary aldosteronism: a new clinical entity.'' Trans Assoc Am Physicians 1955;68:215-31; discussion, 231-3. PMID 13299331.</ref><ref name="urlGrand Rounds: Primary Aldosteronism, Beyond Conn’s Syndrome | Clinical Correlations">{{cite web |url=http://www.clinicalcorrelations.org/?p=1445 |title=Grand Rounds: Primary Aldosteronism, Beyond Conn’s Syndrome | Clinical Correlations |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | ||
* From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling. | * From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling. | ||
Revision as of 18:07, 7 July 2017
Template:Conn syndrome Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
- Primary hyperaldosteronism (Conn's syndrome) was described for the first time by the Polish internist Michał Lityński.[1]
- In 1955, Dr Jerome W. Conn the American endocrinologist first described the condition and named it Conn's syndrome. [2][3]
- From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling.
- On October 19, 1964, Jerome W. Conn, Edwin L. Cohen and David R. Rovner differentiated between primary and secondary aldosteronism in hypertensive disease.[4]
- In 1970s, notwithstanding the extensive application of modern imaging modalities, such as CT scanning, adrenal venous sampling and steroid analysis have remained to be the most accurate and reliable localization method.
- From 1980s, more and more patients with primary aldosteronism were screened out from the hypertensive population by plasma renin activity/plasma aldosterone concentration ratio and cured by surgical interventions; laparoscopic unilateral adrenalectomy has become the generally accepted golden standard of operation.
References
- ↑ Kucharz EJ (2007). "[Michał Lityński--a forgotten author of the first description on primary hyperaldosteronism]". Pol. Arch. Med. Wewn. (in Polish). 117 (1–2): 57–8. PMID 17642209.
- ↑ Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians 1955;68:215-31; discussion, 231-3. PMID 13299331.
- ↑ "Grand Rounds: Primary Aldosteronism, Beyond Conn's Syndrome | Clinical Correlations".
- ↑ Conn JW, Cohen EL, Rovner DR (1985). "Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner". JAMA. 253 (4): 558–66. PMID 3881606.